Quantifying the Benefits of Breastfeeding

Translating these percentages into absolute numbers for a cohort of 10,000 mothers yields:

• 300 cases of postpartum hemorrhage prevented
• 430 breastcancer cases averted
• 200 ovariancancer cases averted
• 150 new cases of type2 diabetes avoided

Economic Valuation

Assigning monetary values to health outcomes clarifies the return on investment (ROI) for breastfeeding support programs.

Direct medical cost savings

Average treatment cost for a case of infant diarrhoea is US$150; respiratory infection costs US$200; a childhood asthma admission averages US$1,200.

Using the avertedcase figures above (per 1,000 births), the annual savings equal:

• Diarrhoea: 120 $150 = **$18,000**
• Respiratory infection: 50 $200 = **$10,000**
• Asthma: 15 $1,200 = **$18,000**

Total infant healthcare savings $46,000 per 1,000 births.

Maternal cost savings

Average treatment cost for breast cancer is US$45,000; ovarian cancer US$55,000; type2 diabetes management US$5,000 per year.

Projected savings for 10,000 mothers:

• Breast cancer: 430 $45,000 = **$19.35M**
• Ovarian cancer: 200 $55,000 = **$11.0M**
• Diabetes: 150 $5,000 = **$0.75M**

Combined maternal savings $31.1M per 10,000 mothers.

Productivity gains

Reduced parental sickleave and higher child cognitive scores increase lifetime earnings. Estimates suggest an average gain of US$7,000 per child for improved cognition and US$1,500 per mother for fewer missed workdays.

For 1,000 children and mothers: $8.5M** in added economic productivity.

Overall ROI

When a community invests US$1M in lactation consultants, maternityroom upgrades, and publiceducation campaigns, the combined healthcare savings, avoided cancer treatment, and productivity gains can exceed US$40M over a 10year horizon an ROI of 40:1.[9]

Measuring Approaches

Robust quantification requires reliable data collection and clear metrics.

1. Breastfeeding prevalence surveys: WHOs Infant and Young Child Feeding (IYCF) questionnaire supplies exclusivebreastfeeding rates at 1, 3, and 6 months.
2. Healthoutcome registries: Linking birthcohort data with hospital discharge and cancer registries enables calculation of averted cases.
3. Economic models: Costofillness (COI) and costeffectiveness analyses (CEA) translate health gains into monetary terms.
4. Longitudinal cohort studies: Followup to age 2030 provides data on chronicdisease risk and lifetime earnings.

Standardized reporting (e.g., the Breastfeeding Impact Assessment Framework released by UNICEF) promotes comparability across regions.

Policy Implications

Quantified benefits underpin several policy actions:

• Maternity leave extensions: 6month paid leave aligns with WHOs recommendation for exclusive breastfeeding.
• Lactationsupport funding: Publicly financed lactation consultants have a documented ROI of 2050:1.
• Workplace accommodations: Dedicated pumping rooms and flexible schedules increase continuation rates, expanding health savings.
• Insurance coverage: Reimbursing breastmilk substitutes only when medically indicated preserves exclusive breastfeeding rates.

When decisions are based on quantified outcomes, resource allocation becomes evidencedriven rather than anecdotal.

Key Takeaways

• Exclusive breastfeeding for six months prevents up to 70% of infant diarrhoea and 40% of respiratory infections.
• Maternal risks of breast and ovarian cancer drop by 45% for each year of breastfeeding.
• Economic analyses consistently show that every dollar invested in breastfeeding support yields >$20 in healthcare savings and productivity gains.
• Standardized data collection and costeffectiveness modeling are essential for transparent, comparable results.
• Policymakers can use these quantified benefits to justify longer maternity leave, workplace lactation spaces, and publichealth campaigns.